BIOCARDIA BCDA 深 沪
等待开盘 09-24 09:30:00 美东时间
1.375
+0.265
+23.87%
华盛通- 最 高1.38
- 今 开1.17
- 成交量 213.23万股
- 最 低 1.17
- 昨 收 1.11
- 总市值 797.67万
- 52周最高 3.20
- 市盈率 静 --
- 换手率 36.76%
- 52周最低 1.00
- 委 比 -87.29%
- 总股本 580.12万
- 历史最高 129.00
- 量 比 0.88
- 振 幅 18.92%
- 历史最低 1.00
- 每 手 1
- 风险率 0.31%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅1650.0%！Ascendiant Capital维持GRI Bio"买入"评级，目标价上调至35美元
今日重点评级关注：Ascendiant Capital：维持GRI Bio"买入"评级，目标价从34美元升至35美元；Ascendiant Capital：维持Atossa Therapeutics"买入"评级，目标价从7.5美元升至7.75美元
09-23 09:52
BioCardia Announces Positive Preliminary Clinical Consultation with Japan Pharmaceutical and Medical Device Agency on Cell Therapy for Ischemic Heart Failure
<p>BioCardia announced positive preliminary clinical consultation with Japan’s PMDA regarding the CardiAMP Heart Failure Trial results. PMDA requested additional details, including clarifications on composite endpoints, statistical power, NTproBNP subgroup rationale, patient target numbers in Japan, and clinical development status in the U.S. BioCardia is preparing responses with formal consultation expected near year-end. CEO Peter Altman expres...
09-22 12:00
BioCardia Raises $5.1 Million Through Stock Sale
BioCardia ( ($BCDA) ) has provided an update. On September 19, 2025, BioCardia,...
09-20 00:47
BioCardia Announces $6 Million Public Offering
An update from BioCardia ( ($BCDA) ) is now available. On September 18, 2025, B...
09-18 21:50
BioCardia Announces CardiAMP Chronic Myocardial Ischemia Trial Top Line Data of Roll-in Cohort Show Improved Exercise Tolerance and Reduced Angina Episodes at Six-Month Primary Follow-up
BioCardia, Inc. announced positive results from its open-label CardiAMP Cell Therapy trial for patients with chronic myocardial ischemia and refractory angina. The minimally invasive therapy showed significant improvement, with patients experiencing an average 80-second increase in exercise tolerance and an 82% reduction in angina episodes at six months. These results outperform existing FDA-approved treatments like Ranolazine and EECP. CardiAMP ...
09-18 11:00
BioCardia CEO Peter Altman to Present at the H. C. Wainwright 27th Annual Global Investment Conference in New York City September 8-10, 2025
Peter Altman, PhD., President and CEO of BioCardia, Inc., will present a corporate update at the H. C. Wainwright 27th Annual Global Investment Conference in New York City on September 10, 2025. His presentation will include recent progress on the company’s clinical cell therapy programs for ischemic heart disease, regulatory activities for CardiAMP® cell therapy and the Helix™ delivery catheter, and updates on partnerships and funding for the Ca...
09-04 13:00
BioCardia and CART-Tech Announce Exclusive Partnership to Develop and Commercialize Heart3D™ Fusion Imaging for Interventional Cardiology
BioCardia and CART-Tech announce an exclusive partnership to develop and commercialize Heart3D™ Fusion Imaging, enhancing 2D X-ray imaging with 3D heart models for cardiac biotherapeutic delivery and biopsy. The system integrates gold-standard MRI and CT images to improve procedural precision. BioCardia gains global exclusive rights for biotherapeutic delivery, while CART-Tech focuses on cardiac resynchronization therapy. The collaboration aims t...
08-13 12:00
BioCardia GAAP EPS of -$0.40
BioCardia press release (NASDAQ:BCDA): Q2 GAAP EPS of -$0.40. Net cash used in operations for the three months ended June 2025 was approximately $1.6 million, as compared to approximately $1.3 million...
08-12 01:58
BioCardia Q2 EPS $(0.40) Beats $(0.50) Estimate
BioCardia (NASDAQ:BCDA) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of $(0.50) by 20 percent. This is a 54.55 percent increase over losses of $(0.88) per share from the same
08-11 21:17
